Human convalescent plasma protects K18-hACE2 mice against severe respiratory disease.

The Journal of General Virology
Joseph Golden Jay W. Hooper

Abstract

SARS-CoV-2 is the causative agent of COVID-19 and human infections have resulted in a global health emergency. Small animal models that reproduce key elements of SARS-CoV-2 human infections are needed to rigorously screen candidate drugs to mitigate severe disease and prevent the spread of SARS-CoV-2. We and others have reported that transgenic mice expressing the human angiotensin-converting enzyme 2 (hACE2) viral receptor under the control of the Keratin 18 (K18) promoter develop severe and lethal respiratory disease subsequent to SARS-CoV-2 intranasal challenge. Here we report that some infected mice that survive challenge have residual pulmonary damages and persistent brain infection on day 28 post-infection despite the presence of anti-SARS-COV-2 neutralizing antibodies. Because of the hypersensitivity of K18-hACE2 mice to SARS-CoV-2 and the propensity of virus to infect the brain, we sought to determine if anti-infective biologics could protect against disease in this model system. We demonstrate that anti-SARS-CoV-2 human convalescent plasma protects K18-hACE2 against severe disease. All control mice succumbed to disease by day 7; however, all treated mice survived infection without observable signs of disease. In marked...Continue Reading

References

Jun 1, 1965·Proceedings of the Society for Experimental Biology and Medicine·H J HEARNW S MILLER
Feb 23, 2020·Science·Daniel WrappJason S McLellan
Apr 1, 2020·Nature·Jian ShangFang Li
Apr 14, 2020·The Journal of Infection·Qing YeJianhua Mao
Apr 18, 2020·The Journal of Experimental Medicine·Betsy J BarnesMikala Egeblad
Apr 26, 2020·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·Silvia NatoliAntonio Pisani
May 1, 2020·The Journal of Experimental Medicine·Santosha A Vardhana, Jedd D Wolchok
May 6, 2020·Journal of Otolaryngology - Head & Neck Surgery = Le Journal D'oto-rhino-laryngologie Et De Chirurgie Cervico-faciale·Claire HopkinsB Nirmal Kumar
May 8, 2020·Nature·Linlin BaoChuan Qin
May 15, 2020·Nature·Sin Fun SiaHui-Ling Yen
May 23, 2020·PLoS Pathogens·Daolin TangRui Kang
May 31, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jasper Fuk-Woo ChanKwok-Yung Yuen
Jun 3, 2020·Cell Host & Microbe·Shi-Hui SunYou-Chun Wang
Jun 6, 2020·Alzheimer's Research & Therapy·Michael T HenekaRobert Brown
Jun 6, 2020·Human Genomics·Cathleen LutzWonyoung Kang
Jun 17, 2020·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Shabnam Salimi, John M Hamlyn
Jun 24, 2020·Proceedings of the National Academy of Sciences of the United States of America·Masaki ImaiYoshihiro Kawaoka
Jul 3, 2020·Frontiers in Neuroanatomy·Marcos F DosSantosVivaldo Moura-Neto
Jul 15, 2020·Journal of Thrombosis and Thrombolysis·Ying-Kiat TanBenjamin Y Q Tan
Aug 5, 2020·BMJ : British Medical Journal·Emily Fraser
Aug 11, 2020·Archivos de bronconeumología·Juan José Rodriguez-SevillaDiego A Rodriguez-Chiaradía
Aug 21, 2020·Signal Transduction and Targeted Therapy·Shuaiyao LuXiaozhong Peng
Aug 21, 2020·BioRxiv : the Preprint Server for Biology·Jian ZhengStanley Perlman
Sep 10, 2020·Journal of Virology·Rebecca L BrocatoJay W Hooper

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.